Clinical Trials
-
Principal Investigator:
Mary R. Welch, MDThe purpose of this study is to evaluate how safe the investigational drug, DSP-0390, is at different doses and to identify a recommended dose that is safe for further study. Investigational means that the study drug is currently being tested and has not been approved for use alone or in combination with any drug by the U.S. Food and Drug Administration (FDA) or any other health or regulatory authority in other countries. DSP-0390 is an oral drug that is being tested in people with high-grade glioma. This drug may help to inhibit or block emopamil binding protein (EBP), a protein that is... -
Principal Investigator:
Mary R. Welch, MDThe purpose of this study is to evaluate how safe the investigational drug, DSP-0390, is at different doses and to identify a recommended dose that is safe for further study. Investigational means that the study drug is currently being tested and has not been approved for use alone or in combination with any drug by the U.S. Food and Drug Administration (FDA) or any other health or regulatory authority in other countries. DSP-0390 is an oral drug that is being tested in people with high-grade glioma. This drug may help to inhibit or block emopamil binding protein (EBP), a protein that is... -
Principal Investigator:
Thomas H. Brannagan III, MDThe main goal of this study is to look at the effect and safety of efgartigimod PH20 SC in people with chronic inflammatory demyelinating polyneuropathy (CIDP). Another goal of the study is to collect information on how well efgartigimod works, how the body processes efgartigimod, what efgartigimod does to the body, and how your immune system reacts to efgartigimod. This trial will be conducted in 2 stages: An open-label Stage A and a randomized-withdrawal, double-blind, placebo-controlled Stage B. Approximately 360 patients aged 18 years and older male and non-pregnant female are planned to... -
Principal Investigator:
Fabio M. Iwamoto, MDThis study is being done to answer the following question: Can we shrink or stabilize your brain cancer by adding immune therapy drugs to the usual radiation therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your recurrent glioblastoma. The usual approach is defined as care most people get for recurrent glioblastoma. -
Principal Investigator:
Fabio M. Iwamoto, MDThis study is being done to answer the following question: Can we shrink or stabilize your brain cancer by adding immune therapy drugs to the usual radiation therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your recurrent glioblastoma. The usual approach is defined as care most people get for recurrent glioblastoma. -
Principal Investigator:
Thomas H. Brannagan III, MDThe purpose of this study is to evaluate the safety, tolerability, and effectiveness of VX-548 in participants with pain due to Diabetic Peripheral Neuropathy (DPN). To be in this study you must have DPN and be 18 through 80 years of age, inclusive, with presence of bilateral pain in lower extremities due to DPN for at least 1 year. -
Principal Investigator:
Thomas H. Brannagan III, MDThe purpose of this study is to evaluate the safety, tolerability, and effectiveness of VX-548 in participants with pain due to Diabetic Peripheral Neuropathy (DPN). To be in this study you must have DPN and be 18 through 80 years of age, inclusive, with presence of bilateral pain in lower extremities due to DPN for at least 1 year. -
Principal Investigator:
Rebecca Straus Farber, MDThe purpose of this study is to evaluate the differences between immune profiles of individuals remaining on Ocrelizumab/Rituximab versus those transitioning to diroximel fumarate at two years. Baseline visits for subjects transitioning to diroximel fumarate (DRF) will take place 6 months after last Ocrelizumab (OCR) or Rituximab (RTX) dose, prior to beginning DRF. Baseline visit for individuals remaining on OCR/RTX will take place prior to OCR/RTX dose. Visits will occur every 6 months for 24 months (total of 5 study visits). Visits will include blood draw as well as clinical assessments. -
Principal Investigator:
Philip L. De Jager, MD, PHDGenes and Environment in MS (GEMS) is a longitudinal cohort study investigating how genetics and environment can lead to the onset of Multiple Sclerosis. We are recruiting first-degree relatives (siblings, parents, and children) of people who have been diagnosed with MS. This study involves the collection of biological specimen, including saliva and blood, as well as the completion of questionnaires regarding personal and family health history, diet, and other environmental exposures. The goal of this study is to use these data to develop and test an algorithm predicting risk of MS onset that... -
Principal Investigator:
Philip L. De Jager, MD, PHDGenes and Environment in MS (GEMS) is a longitudinal cohort study investigating how genetics and environment can lead to the onset of Multiple Sclerosis. We are recruiting first-degree relatives (siblings, parents, and children) of people who have been diagnosed with MS. This study involves the collection of biological specimen, including saliva and blood, as well as the completion of questionnaires regarding personal and family health history, diet, and other environmental exposures. The goal of this study is to use these data to develop and test an algorithm predicting risk of MS onset that...